Regulations: U.S. Food and Drug Administration (OPDP / CBER Advertising and Promotional Labeling Branch)

FDA Draft Guidance - Character-Space-Limited Platforms

On character-limited platforms (paid search, short posts, SMS), a prescription drug benefit claim should be accompanied in the same unit by the established name, the most serious risks and a direct link to complete risk information, or the claim should not be made there.

FDA Rx DTC Broadcast - Major Statement in Clear, Conspicuous and Neutral Manner

Consumer-directed TV, radio and streaming ads for prescription drugs must include a major statement of the major risks presented in a clear, conspicuous and neutral manner (consumer-friendly language, audio as clear as the rest of the ad, concurrent text on TV, no distractions), plus adequate provision for full labeling.

FDA Rx Promotion - Comparative and Uniqueness Claims

Claims that a prescription product is safer, more effective, the only or the first compared with other products require substantial evidence, normally head-to-head data, and must be accurately qualified; compounded drugs must not be marketed as FDA-approved or equivalent to a brand.

Get a free homepage compliance scan